Read + Share
Jain V, Gimenez-Arnau A, Hayama K, Reich A, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in
chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol 2024;153:479-486.
PMID: 37866460
|
 |
|
Jain V, Gimenez-Arnau A, Hayama K, Reich A, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in
chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol 2024;153:479-486.
PMID: 37866460
|
|
|
|